Roche's New Breast-Cancer Drug Supports Midterm Growth Outlook

Dow Jones09-29 21:50

1350 GMT - Roche Holding provided an encouraging update on its plans for a new breast-cancer drug, which together with other upcoming product launches underscore the company's confidence in its growth through the end of the decade, Citi analysts say. The Swiss drugmaker signaled it is comfortable with 2027 consensus estimates for sales of its breast-cancer drug, giredestrant, of 600 million Swiss francs, Citi says in a research note. Roche plans a patient-assistance program, offering the drug for free to some patients initially to reduce access barriers with the hope of seeing a "hockey-stick" launch trajectory, the analysts say. Citi expects the sales impact to be covered by 2028, and reiterates its forecast of annual peak sales of $14.5 billion. Shares fall 1.2%.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment